Skip to main content
Equibles
IMCR logo

IMCR

Immunocore Holdings plc
$31.95 -1.13 (-3.42%) At close · Jul 10
Market Cap
$1.63B
Shares
50,865,574

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$31.95 Open$32.93 Day$31.78–32.97 52W$27.56–40.72 Avg vol 30d592K Short int9.0M · 17.7% float · 12.5d Short vol16% Last earningsFeb 25, 2026 DataFeb 2021–Jul 2026 Filing10-Q · May 6
Up next
Next earnings call
Sep 10, 2026 Est · unconfirmed · in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 6, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol High
      Market backdrop VIX 17.2 · elevated Equity put/call 0.55
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg −2%
      below
      Price vs 50-day avg +8%
      above
      RSI (14) 57
      neutral
      MACD trend Positive
      52-week position 33%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +15%
      trailing
      6-month return −2%
      trailing
      YTD return −8%
      this year
      Relative strength −12%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $30 › 200d $33 — 200d above 50d
      Institutional flow Accumulating
      5 of 144 funds reported for Jun 30 · net +3.6K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      17.68% of float · ▼ -0.5% MoM · 12.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      144 holders — mid 3-yr range
      Squeeze score 72
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +43%
      Y/Y
      EPS growth +30%
      Y/Y
      Free cash flow $-15.1M
      Balance sheet $467.7M
      net cash
      Quant / Vol
      risk profile
      High
      Volatility 38%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 4.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 5 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −2% Neutral
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      57 Neutral
      MACD trend
      Positive Bullish
      52-week position
      33% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $30 › 200d $33 — 200d above 50d
      Institutional flow Accumulating
      5 of 144 funds reported for Jun 30 · net +3.6K sh shares · +1 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      17.68% of float · ▼ -0.5% MoM · 12.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      144 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $28 Now $32 · 33% 52-wk high $41
      vs 200-day avg -2% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      countries where KIMMTRAK is launched 30 FY 2025 —
      mean duration of treatment 14 FY 2025 —
      cash, cash equivalents and marketable securities $864M as of December 31, 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      IMCR
      Immunocore Holdings plc
      this stock
      		$1.63B -8.0% +43.1% — 17.7%
      ONC
      BeOne Medicines Ltd.
      		 $431.70B -1.7% +22179.2% 878.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $123.19B +7.1% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.67B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      		 $54.85B +4.4% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      145
      % held
      106.6%
      Reported
      5 of 144
      Top holder
      RTW INVESTMENTS, LP
      Held Float
      View
      Held by Funds
      Fund positions
      71
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      9.0M
      Days to cover
      12.5d
      Change
      -47.1K sh
      View
      Short Volume
      Short vol %
      16%
      As of
      Jul 13, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      15
      Value
      $424
      As of
      Jun 8, 2026
      View
      Off-Exchange
      Off-exchange %
      54.4%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $400.0M
      Net income (FY)
      $-35.5M
      EPS diluted
      $-0.71
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $385.3K
      Shares
      11.8K
      Filed
      Mar 11, 2026
      View
      Exempt Offerings
      Offering
      $140.0M
      Filed
      Jul 28, 2022
      View
      Earnings & Events
      Earnings Calls
      Last call
      Apr 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      IMCR -1.7% +14.5% -2.4% +0.6% -8.0%
      SPY +1.4% +4.1% +9.1% +1.1% +10.7%
      vs SPY -3.1% +10.5% -11.5% -0.5% -18.7%
      Key facts CIK 1671927 CUSIP 45258D105 13F (30d) 5 filings 5 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)